Stay updated on Safety of Intravitreal APL-2 in Geographic Atrophy Clinical Trial
Sign up to get notified when there's something new on the Safety of Intravitreal APL-2 in Geographic Atrophy Clinical Trial page.

Latest updates to the Safety of Intravitreal APL-2 in Geographic Atrophy Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedMajor update: adds current operating status notice and links for NIH Clinical Center, and bumps version to v3.2.0, replacing the old v3.1.0.SummaryDifference4%
- Check16 days agoChange DetectedVersion update: from v3.0.2 to v3.1.0. The change is limited to the revision label; no core content or critical data appears to be altered.SummaryDifference0.1%
- Check23 days agoNo Change Detected
- Check31 days agoChange DetectedUpdated the page revision from v3.0.1 to v3.0.2 and removed the Back to Top element.SummaryDifference0.2%
- Check38 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content or other important elements.SummaryDifference0.2%
- Check45 days agoChange DetectedThe web page has been updated to include a new facility name, location details, and a list of publications related to pegcetacoplan treatment for geographic atrophy in age-related macular degeneration. Additionally, the revision number has been updated to v3.0.0.SummaryDifference6%
- Check59 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%
Stay in the know with updates to Safety of Intravitreal APL-2 in Geographic Atrophy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety of Intravitreal APL-2 in Geographic Atrophy Clinical Trial page.